NCT02316106 2025-04-27
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
Clinical Trials
6 trialsNCT01302886 2020-12-17
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
Novartis
Phase 2 Completed
NCT01441973 2018-01-23
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bristol-Myers Squibb
Phase 2 Completed
NCT01718899 2016-09-28
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
OncoPep, Inc.
Phase 1 Completed
NCT01219010 2015-01-19
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT01222286 2014-05-09
KIRMONO
Innate Pharma
Phase 2 Completed